drug · protein
lutetium Lu 177 vipivotide tetraxetan
Marketedupdated 6mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for prostate cancer and 6 investigational indications.
targets
Glutamate carboxypeptidase 2
all catalysts(4)
approval · 4
Mar 23, 2022
approval
$NVS151.34-2.49%
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Mar 28, 2025
approval
$NVS151.34-2.49%
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Mar 28, 2025
approval
$NVS151.34-2.49%
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Apr 7, 2026
approval
$NVS151.34-2.49%
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Trials studying lutetium Lu 177 vipivotide tetraxetan
- phase2Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
- phase2Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
- phase2Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
- phase2Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
- phase2Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- phase2Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- phase2ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
- EP1A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 23, 2027
123 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Sep 18, 2041method-of-use (U-4169)US 12208102
- Nov 12, 2035method-of-use (U-4169)US 11951190
- Oct 17, 2034compositionUS 10398791
- Aug 15, 2028compositionUS 104062401.7y
- Aug 15, 2028compositionUS 113181211.7y
FDA exclusivities (2)
- Mar 28, 2028I-965Indication (3y)1.4y
- Mar 23, 2027NCENew Chemical Entity (5y)123d
News(10)
- PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMOLess than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.biospace · 6d ago
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameLilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.biopharma_dive · 20d ago
- Molecular Partners to lay off up to 44% of workforce in radiotherapy pivotMolecular Partners plans to lay off up to 44% of its staff as it focuses its declining cash reserves on a radiotherapeutic pipeline led by an early-phase small cell lung cancer drug candidate.fiercebiotech · 20d ago
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- 3 steps for taking on Novartis in radiopharma: Curium up firstTo successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.biospace · 1mo ago
- Novartis bets up to $900M for radioligand therapy from China’s BoomRayNovartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.biospace · 1mo ago
- Novartis secures new radioligand in $900M deal as competition strengthensAs an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.fiercebiotech · 1mo ago
- Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapiesDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 1mo ago
- Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 1mo ago
- Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&AAside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…biospace · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that